ArticleThe Journal of thoracic and cardiovascular surgery2026
Volume-outcome relationship of mortality following surgical explant of transcatheter aortic valve replacements.
Article in The Journal of thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo evaluate the relationship between hospital volume of transcatheter aortic valve replacement (TAVR) explants and postoperative mortality.
methodsThe Center for Medicare & Medicaid Services was queried from 2016 to 2024 for patients who underwent TAVR explant. The study period was divided into 2 eras: early (2016-2021) and recent (2022-2024). Hospitals were classified grouped as low volume or high volume. Both 30-day and 1-year mortality were compared, and multivariable analysis was performed.
resultsWe identified a total of 123 TAVR explants during the study period. Of the 375 hospitals that performed at least 1 TAVR explant, 235 (63%) performed fewer than 3 explants. Postoperative mortality was 13.3% at 30 days and 18.3% at 1 year. Thirty-day mortality was higher in low-volume hospitals compared to high-volume hospitals in the early era (17% vs 9.68%; P = .029), but not in the recent era (11.0% vs 13.4%; P = .409). At low-volume hospitals, both 30-day and 1-year mortality were higher following concomitant TAVR explant compared to isolated TAVR explant (19.9% vs 9.3% [P < .001] and 25.4% vs 13.6% [P < .001], respectively), but not in high-volume hospitals (14% vs 8.78% [P = .148] and 18.3% vs 15.5% [P = .518], respectively). On multivariable analysis, high-volume hospital status was associated with lower mortality for the early era (odds ratio [OR], 0.48; 95% confidence interval [CI], 0.25-0.95), but not for the recent era (OR, 1.30; 95% CI, 0.71-2.38) or the total cohort (OR, 0.80; 95% CI, 0.51-1.24).
conclusionsWhile a hospital volume-outcome relationship to TAVR explant mortality existed in the early era, recent data suggest no volume-outcome relationship. With the lack of a volume-outcome relationship, TAVR explant will become a fundamental cardiac surgical procedure. High-risk concomitant surgery may benefit from high-volume hospital management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.